Since 2021, only three anti-amyloid antibodies have been approved by the Food and Drug Administration (FDA) for the treatment of AD, and in HD, all huntingtin-lowering approaches using antisense oligonucleotides have failed to meet clinical endpoints. Here, HTT is linked to Alzheimer disease.